<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZELAPAR- selegiline hydrochloride tablet, orally disintegrating </strong><br>Valeant Pharmaceuticals North America LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ZELAPAR safely and effectively. See full prescribing information for ZELAPAR.<br><br>ZELAPAR (selegiline hydrochloride) ORALLY DISINTEGRATING TABLETS<br>Initial U.S. Approval: 2006</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Warnings and Precautions </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> <a href="#Section_5.3">(5.3)</a>                    07/2014 </p>
<p class="Highlighta">Impulse Control/Compulsive Behaviors <a href="#Section_5.7">(5.7)</a>       07/2014 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">ZELAPAR, a monoamine oxidase type B (MAO-B) inhibitor, is indicated as an adjunct in the management of patients with Parkinson’s disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy (<a href="#Section_1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Initiate treatment with 1.25 mg given once a day for at least 6 weeks; after 6 weeks, the dose may be escalated to 2.5 mg once a day <a href="#Section_2.1">(2.1</a>)</dd>
<dt>•</dt>
<dd>Place tablet on top of the tongue where the tablet will disintegrate in seconds; avoid food and liquid intake 5 minutes before and after each dose <a href="#Section_2.1">(2.1</a>)</dd>
<dt>•</dt>
<dd>In patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the dose should be reduced to 1.25 mg; ZELAPAR is not recommended in patients with severe (Child-Pugh score &gt;9) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#Section_2.2">2.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Orally Disintegrating Tablets: 1.25 mg (<a href="#Section_3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">ZELAPAR is contraindicated in patients using the following drugs: meperidine, tramadol, methadone, propoxyphene, MAO inhibitors including selective MAO-B inhibitors, dextromethorphan, St. John’s wort, and cyclobenzaprine (<a href="#Section_4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> above 2.5 mg/day <a href="#Section_5.1">(5.1)</a>
</dd>
<dt>•</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> when used with antidepressants <a href="#Section_5.2">(5.2)</a>
</dd>
<dt>•</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep during activities of daily living <a href="#Section_5.3">(5.3)</a>
</dd>
<dt>•</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> <a href="#Section_5.4">(5.4)</a>
</dd>
<dt>•</dt>
<dd>May cause or exacerbate <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> <a href="#Section_5.5">(5.5)</a>
</dd>
<dt>•</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior <a href="#Section_5.6">(5.6)</a>
</dd>
<dt>•</dt>
<dd>May cause problems with impulse control and compulsive behaviors <a href="#Section_5.7">(5.7)</a>
</dd>
<dt>•</dt>
<dd>Abrupt discontinuation may cause <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> <a href="#Section_5.8">(5.8)</a>
</dd>
<dt>•</dt>
<dd>Increased risk of melanoma <a href="#Section_5.9">(5.9)</a>
</dd>
<dt>•</dt>
<dd>May cause irritation of the buccal mucosa <a href="#ID_fff0680a-257d-443c-810f-e5c15b165a66">(5.10)</a>
</dd>
<dt>•</dt>
<dd>Increased risk for phenylketonuric patients (<a href="#ID_cd4abdcd-02a5-40aa-9cab-0bf32857be28">5.11</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (incidence at least 3% greater than on placebo) are <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorders</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> <a href="#Section_6.1">(6.1)</a> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or contact FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy: Based on animal data, may cause fetal harm (<a href="#Section_8.1">8.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: ZELAPAR is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr &lt;30mL/min) (<a href="#Section_2.3">2.3</a>, <a href="#ID_86ea3571-fbd0-48c3-b390-fd5443a9e3aa">8.7</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div><div></div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div><div><div></div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1     INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1  General Dosage Recommendations</a></h2>
<h2><a href="#section-2.2" class="toc">2.2  Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3  Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep During Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>/<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-Like Behavior</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Impulse Control/Compulsive Behaviors</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Withdrawal Emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Melanoma</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Irritation of the Buccal Mucosa</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Risk for Phenylketonuric Patients</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Effect on Renal Function</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Meperidine</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Dextromethorphan</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 MAO Inhibitors</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Sympathomimetic Medications</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Tyramine/Selegiline Interaction</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Drugs that Induce CYP450</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Dopaminergic Antagonists</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Selegiline</a></h2>
<h2><a href="#section-9.2" class="toc">10.2 <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> with Non-Selective MAO Inhibitors</a></h2>
<h2><a href="#section-9.3" class="toc">10.3 Treatment of Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1     INDICATIONS AND USAGE</h1>
<p class="First">ZELAPAR is indicated as an adjunct in the management of patients with Parkinson’s disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that ZELAPAR has any beneficial effect in the absence of concurrent levodopa therapy [see <span class="Italics"><a href="#Section_14">Clinical Studies (14</a><a href="#Section_14">)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1  General Dosage Recommendations</h2>
<p class="First">Initiate treatment with 1.25 mg given once a day for at least 6 weeks. After 6 weeks, the dose may be increased to 2.5 mg given once a day if a desired benefit has not been achieved and the patient is tolerating ZELAPAR. There is no evidence that doses greater than 2.5 mg a day provide additional benefit, and they should ordinarily be avoided because of the potential increased risk of adverse events.</p>
<p>Take ZELAPAR in the morning before breakfast and without liquid. Patients should avoid ingesting food or liquids for 5 minutes before and after taking ZELAPAR.</p>
<p>Patients should not attempt to push ZELAPAR through the foil backing. Patients should PEEL BACK the backing of one or two <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> (as prescribed) with dry hands, and GENTLY remove the tablet(s). Patients should IMMEDIATELY place the ZELAPAR tablet(s) on top of the tongue where it will disintegrate in seconds. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2  Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> (Child-Pugh score 5 to 9), the daily dose of ZELAPAR should be reduced (from 2.5 to 1.25 mg daily), depending on the clinical response. ZELAPAR is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score greater than 9)[see <span class="Italics"><a href="#ID_c2b674a6-32f4-4221-a2fa-add0241ad02d">Use in Specific Populations (8.6)</a></span> and <span class="Italics"><a href="#Section_12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3  Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment of ZELAPAR is required in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance [CLcr] 30 to 89 mL/min). The maintenance dose of ZELAPAR (1.25 mg or 2.5 mg) is determined by the individual clinical response.  ZELAPAR is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> [ESRD] (creatinine clearance [CLcr] &lt;30 mL/min) [see <span class="Italics"><a href="#ID_86ea3571-fbd0-48c3-b390-fd5443a9e3aa">Use in Specific Populations (8.7)</a></span> and <span class="Italics"><a href="#Section_12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ZELAPAR Orally Disintegrating Tablets contain 1.25 mg selegiline hydrochloride. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">ZELAPAR is contraindicated in patients using meperidine, tramadol, methadone, or propoxyphene. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>, a potentially serious condition, which can result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported with concomitant use of meperidine (e.g., Demerol and other trade names). At least 14 days should elapse between discontinuation of ZELAPAR and initiation of treatment with these medications [see<span class="Italics"><a href="#Section_5.2"> Warnings and Precautions (5.2)</a></span>]. </p>
<p>ZELAPAR is contraindicated in patients on any other MAO inhibitor (selective or non-selective), because of an increased risk for <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>.  At least 14 days should elapse between discontinuation of ZELAPAR and initiation of treatment with any MAO inhibitor.</p>
<p>ZELAPAR is contraindicated in patients using St. John’s wort, or cyclobenzaprine (a tricyclic muscle relaxant).</p>
<p>ZELAPAR is contraindicated in patients using dextromethorphan, because of reported episodes of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> or <span class="product-label-link" type="condition" conceptid="4092397" conceptname="Bizarre behavior">bizarre behavior</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">ZELAPAR should not be used at daily doses exceeding those recommended (2.5 mg/day) because of the risks associated with non-selective inhibition of MAO [see <span class="Italics"><a href="#ID_2bbd5626-59dc-4fe7-bf3d-41d4da449ac6">Drug Interactions (7.3)</a></span> and <span class="Italics"><a href="#Section_12.2">Clinical Pharmacology (12.2)</a></span>].</p>
<p>The selectivity of ZELAPAR for MAO-B may not be absolute even at the recommended daily dose of 2.5 mg a day. The selectivity of MAO-B inhibitors, typically decreases and it is ultimately lost as the dose is increased beyond recommended doses. Hypertensive reactions associated with ingestion of tyramine containing foods have been reported even in patients taking the recommended daily dose of swallowed selegiline, a dose which is generally believed to be selective for MAO-B. Selectivity for MAO-B inhibition is gradually lost with increasing daily doses. An increase in tyramine sensitivity for blood pressure responses appears to begin at a dose of 5 mg ZELAPAR daily [see <span class="Italics"><a href="#ID_726c5147-dd29-40b6-a9be-4732da21e958">Drug Interactions (7.5)</a></span>]. However, the precise dose at which ZELAPAR becomes a non-selective inhibitor of all MAO enzymes in individual patients is unknown.</p>
<p>Reports of hypertensive reactions have occurred in patients who ingested tyramine-containing consumables (i.e., food or drink) while receiving swallowed selegiline at the recommended dose (a dose believed to be relatively selective for MAO-B).</p>
<p>The safe use of ZELAPAR at doses above 2.5 mg daily without dietary tyramine restrictions has not been established. </p>
<p>A pharmacodynamic study showed increased tyramine sensitivity for increasing blood pressure and decreased selectivity for MAO-B with dosing above the recommended level (2.5 mg daily)[see<span class="Italics"><a href="#Section_12.2"> Clinical Pharmacology (12.2)</a></span>].</p>
<p><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). </p>
<p>After starting ZELAPAR, monitor patients for new onset <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or exacerbation of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> that is not adequately controlled.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> and <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span> have been reported with the combined treatment of an antidepressant (e.g., selective serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a non-selective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (Eldepryl), rasagiline (AZILECT), and Zydis selegiline (ZELAPAR). </p>
<p><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> is a potentially serious condition, which can result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Typical clinical signs and symptoms include behavioral and cognitive/<span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), autonomic effects (e.g., <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>/<span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>), and somatic effects (e.g., muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span> manifested by <span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonus</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>).</p>
<p>In the post-marketing period, fatal and non-fatal cases of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported in patients treated with antidepressants concomitantly with ZELAPAR [see <span class="Italics"><a href="#Section_4">Contraindications (4)</a></span> and <span class="Italics">Drug Interactions (<a href="#ID_c850e4bd-10d8-47ee-8d7b-d1b4d01ba186">7.1</a>, <a href="#ID_c14db45d-6e02-45f8-a0ed-0c3f85d728ea">7.2</a>, <a href="#ID_2bbd5626-59dc-4fe7-bf3d-41d4da449ac6">7.3</a>)</span>]. </p>
<p>Clinical studies of ZELAPAR did not allow concomitant use of any selective serotonin re-uptake inhibitor (e.g., fluoxetine-Prozac, fluvoxamine-Luvox, paroxetine-Paxil, sertraline, venlafaxine-Effexor, or nefazadone-Serzone) or any non-selective serotonin reuptake inhibiting antidepressant drug (except when taken at a low dose and only at night for the purpose of effective sleep) with ZELAPAR. </p>
<p>Because the mechanisms responsible for these reactions are not fully understood, avoid the combination of ZELAPAR with any antidepressant. At least 14 days should elapse between discontinuation of ZELAPAR and initiation of treatment with a SSRI, SNRI, tricyclic, tetracyclic, or triazolopyridine antidepressant. In patients taking antidepressants with a long half-life (e.g., fluoxetine and its active metabolite), allow at least five weeks (perhaps longer, especially if fluoxetine has been prescribed chronically and/or at higher doses) to elapse between discontinuation of fluoxetine and initiation of ZELAPAR [see<span class="Italics"><a href="#ID_b9d3cfd7-1deb-4981-9380-330fd081c1a6"> Drug Interactions (7.6)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep During Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Patients with Parkinson’s disease treated with ZELAPAR or other drugs increasing dopaminergic tone have reported <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes resulted in <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span>. Although many of these patients reported <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, some did not perceive warning signs, such as excessive <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and believed that they were alert immediately prior to the event. Some of these events have been reported as late as one year after initiation of treatment. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">It has been reported that <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while engaged in activities of daily living always occurs in a setting of pre-existing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, although patients may not give such a history. For this reason, prescribers should reassess patients for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> especially since some of the events occur well after the start of treatment.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> may occur in patients receiving ZELAPAR. There was an increased risk for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> in geriatric patients (&gt;65 years) vs non-geriatric patients treated with ZELAPAR. Prescribers should also be aware that patients may not acknowledge <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> until directly questioned about <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> during specific activities. Patients should be advised to exercise caution while driving, operating machines, or working at heights during treatment with ZELAPAR. Patients who have already experienced <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and/or an episode of sudden sleep onset should not participate in these activities during treatment with ZELAPAR.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Before initiating treatment with ZELAPAR, advise patients about the potential to develop <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and specifically ask about factors that may increase this risk, such as concomitant sedating medications and the presence of <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>. If a patient develops <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">daytime sleepiness</span> or episodes of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep during activities that require active participation (e.g., conversations, eating, etc.), ZELAPAR should ordinarily be discontinued. If a decision is made to continue ZELAPAR, patients should be advised not to drive and to avoid other potentially dangerous activities. There is insufficient information to establish whether dose reduction will eliminate episodes of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while engaged in activities of daily living</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></h2>
<p class="First">Assessments of orthostatic (supine and standing) blood pressures at different times throughout the 12 week study period in two controlled trials showed that the frequency of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (&gt;20 mm Hg decrease in systolic blood pressure and/or &gt;10 mm Hg decrease in diastolic blood pressure) was greater with ZELAPAR treatment than with placebo treatment. Patients taking ZELAPAR were most likely to experience a decline in systolic and diastolic blood pressure at 8 weeks (2 weeks after initiating 2.5 mg ZELAPAR). At that time, the incidence of systolic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> was about 21% in ZELAPAR-treated patients and 9% in placebo-treated patients. The incidence of diastolic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> was about 12% in ZELAPAR-treated patients and about 4% in placebo-treated patients. Thus, it appears that there may be an increased risk for <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in the period after increasing the daily dose of ZELAPAR<span class="Sup">®</span> from 1.25 to 2.5 mg.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> was higher in geriatric patients (≥65 years) than in non-geriatric patients. In the geriatric patients, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> occurred in about 3% of ZELAPAR-treated patients compared to 0% of placebo-treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></h2>
<p class="First">ZELAPAR may potentiate dopaminergic side effects of levodopa and may cause <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> or exacerbate preexisting <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>. In controlled trials, the incidence of <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> was 6% in ZELAPAR-treated patients and 3% in placebo-treated patients. Decreasing the dose of levodopa may lessen <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>. The incidence of <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> causing study discontinuation was greater on ZELAPAR than on placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>/<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-Like Behavior</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6.1"></a><a name="section-5.6.1"></a><p></p>
<p class="First">In controlled trials, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span> was reported by 4% of ZELAPAR-treated patients and 2% in placebo-treated patients. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> led to drug discontinuation and premature withdrawal from clinical trials in about 1% of ZELAPAR-treated patients, compared to no patient on placebo. </p>
<p>Postmarketing reports indicate that patients may experience new or worsening mental status and behavioral changes, which may be severe, including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior during ZELAPAR treatment or after starting or increasing the dose of ZELAPAR. Other drugs prescribed to improve the symptoms of Parkinson’s disease can have similar effects on thinking and behavior. This <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span> and behavior can consist of one or more of a variety of manifestations including paranoid ideation, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>. </p>
<p>Patients with a major <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic disorder</span> should ordinarily not be treated with ZELAPAR because of the risk of exacerbating <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. In addition, certain medications used to treat <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of ZELAPAR [see <span class="Italics"><a href="#ID_045473b3-ac3e-4c22-864f-808db567e565"> Drug Interactions (7.8)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6.2"></a><a name="section-5.6.2"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Impulse Control/Compulsive Behaviors</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Case reports suggest that patients can experience intense urges to gamble, increased sexual urges, intense urges to spend money, <span class="product-label-link" type="condition" conceptid="4086349" conceptname="Binging">binge eating</span>, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including ZELAPAR, that increase central dopaminergic tone and that are generally used for the treatment of Parkinson’s disease. In some cases, although not all, these urges were reported to have stopped when the dose was reduced or the medication was discontinued. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their caregivers about the development of new or increased <span class="product-label-link" type="condition" conceptid="4023166" conceptname="Gambling">gambling</span> urges, sexual urges, uncontrolled spending, <span class="product-label-link" type="condition" conceptid="4086349" conceptname="Binging">binge eating</span>, or other urges while being treated with ZELAPAR. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking ZELAPAR</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Withdrawal Emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></h2>
<p class="First">Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> (characterized by elevated temperature, muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, altered consciousness, and <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span>), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in antiparkinsonian therapy. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Melanoma</h2>
<p class="First">Epidemiological studies have shown that patients with Parkinson’s disease have a higher risk (2- to approximately 6-fold higher) of developing melanoma than the general population. Whether the increased risk observed was due to Parkinson’s disease or other factors, such as drugs used to treat Parkinson’s disease, is unclear. </p>
<p>For the reasons stated above, patients and providers are advised to monitor for melanomas frequently and on a regular basis when using ZELAPAR for any indication. Ideally, periodic skin examinations should be performed by appropriately qualified individuals (e.g., dermatologists).</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_fff0680a-257d-443c-810f-e5c15b165a66"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Irritation of the Buccal Mucosa</h2>
<p class="First">In the controlled clinical trials, periodic examinations of the tongue and oral mucosa were performed. At the end of the study, the frequency of mild oropharyngeal abnormality (e.g., swallowing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4012068" conceptname="Sore mouth">mouth pain</span>, discrete areas of focal reddening, multiple foci of reddening, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and/or ulceration) in patients without similar abnormality at baseline was 10% in ZELAPAR-treated patients compared to 3% in placebo-treated patients. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_cd4abdcd-02a5-40aa-9cab-0bf32857be28"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Risk for Phenylketonuric Patients</h2>
<p class="First">It is important to note that each ZELAPAR tablet contains 1.25 mg phenylalanine (a component of aspartame). Patients taking the 2.5 mg dose of ZELAPAR will receive 2.5 mg phenylalanine.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_80ad999e-d2c0-4ea2-8625-f6e642b359f2"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Effect on Renal Function</h2>
<p class="First">Small increments in serum BUN and creatinine have been observed in patients treated with high dose ZELAPAR (10 mg daily; 4 times the recommended dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail in the Warnings and Precautions section of labeling.</p>
<dl>
<dt>•</dt>
<dd>Risk for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> [see <span class="Italics"><a href="#Section_5.1">Warnings and Precautions (5.1)</a></span>]</dd>
<dt>•</dt>
<dd>Risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> [see <span class="Italics"><a href="#Section_5.2">Warnings and Precautions (5.2)</a></span>]</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep During Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> [see <span class="Italics"><a href="#Section_5.3">Warnings and Precautions (5.3)</a></span>]</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> [see<span class="Italics"><a href="#Section_5.4"> Warnings and Precautions (5.4)</a></span>]</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span> [see<span class="Italics"><a href="#Section_5.5"> Warnings and Precautions (5.5)</a></span>]</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>/<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-Like Behavior [see<span class="Italics"><a href="#Section_5.6"> Warnings and Precautions (5.6)</a></span>]</dd>
<dt>•</dt>
<dd>Impulse Control / Compulsive Behaviors [see <span class="Italics"><a href="#Section_5.7">Warnings and Precautions (5.7)</a></span>]</dd>
<dt>•</dt>
<dd>Withdrawal Emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span> [see <span class="Italics"><a href="#Section_5.8">Warnings and Precautions (5.8)</a></span>]</dd>
<dt>•</dt>
<dd>Melanoma [see <span class="Italics"><a href="#Section_5.9">Warnings and Precautions (5.9)</a></span>]</dd>
<dt>•</dt>
<dd>Irritation of the Buccal Mucosa [see <span class="Italics"><a href="#ID_fff0680a-257d-443c-810f-e5c15b165a66">Warnings and Precautions (5.10)</a></span>]</dd>
<dt>•</dt>
<dd>Risk for Phenylketonuric Patients [see <span class="Italics"><a href="#ID_cd4abdcd-02a5-40aa-9cab-0bf32857be28">Warnings and Precautions (5.11)</a></span>]</dd>
<dt>•</dt>
<dd>Effect on Renal Function [see <span class="Italics"><a href="#ID_80ad999e-d2c0-4ea2-8625-f6e642b359f2">Warnings and Precautions (5.12)</a></span>]</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, the incidence of adverse reactions (number of unique patients experiencing an adverse reaction per total number of patients treated) observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the incidence of adverse reactions observed in clinical practice.</p>
<p>Because the controlled trials performed during premarketing development both used a titration design (1.25 mg per day for 6 weeks, followed by 2.5 mg per day for 6 weeks), with a resultant confounding of time and dose, it was impossible to adequately evaluate the effects of dose on the incidence of adverse events.</p>
<p>The most common adverse reactions (treatment difference incidence at least 3% greater than placebo incidence) reported in the double-blind, placebo-controlled trials during ZELAPAR treatment were <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorders</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (See <a href="#_Ref395251470">Table 1</a>).</p>
<p>Of the 194 patients treated with ZELAPAR in the double-blind, placebo-controlled trials, 5% discontinued due to adverse reactions compared to 1% of the 98 patients who received placebo. Most common adverse reactions causing discontinuation of treatment included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.1"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Incidence in controlled clinical trials</span></p>
<p><a href="#_Ref395251470">Table 1</a> lists the adverse events reported in the placebo-controlled trials after at least one dose of ZELAPAR (incidence 2% or greater). </p>
<a name="_Ref395251470"></a><table width="90.04%">
<caption><span>Table 1: Treatment-Emergent Adverse Events<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> Incidence in Double-Blind, Placebo-Controlled Trials (Events ≥2% of Patients Treated with ZELAPAR and Numerically More Frequent than the Placebo Group)</span></caption>
<col width="35%">
<col width="27%">
<col width="38%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold"><span class="Underline">Body System/</span></span><br><span class="Bold"><span class="Underline">Adverse Event</span></span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold"><span class="Underline">ZELAPAR</span></span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a><br><span class="Bold"><span class="Underline">1.25/2.5 mg</span></span><br><span class="Bold"><span class="Underline">N=194</span></span><br><span class="Bold"><span class="Underline">%</span></span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold"><span class="Underline">Placebo</span></span><a href="#footnote-2" class="Sup">†</a><br><span class="Bold"><span class="Underline">N=98</span></span><br><span class="Bold"><span class="Underline">%</span></span>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Patients may have reported multiple adverse experiences during the study or at discontinuation; thus patients may be included in more than one category.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Patients received concomitant levodopa.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin disorders</span> represent any new skin abnormality that would not be characterized as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or neoplastic lesion.  These include events such as <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span>, skin <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, herpes simplex, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3"><p class="First"><span class="Bold"><span class="Underline">Body as a Whole</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Botrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold"><span class="Underline">Cardiovascular System</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold"><span class="Underline">Digestive System</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></p></td>
<td class="Botrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">Tooth Disorder</span></p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold"><span class="Underline">Hemic and Lymphatic System</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold"><span class="Underline">Metabolic and Nutritional Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold"><span class="Underline">Musculoskeletal System</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg Cramps</span></p></td>
<td class="Botrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold"><span class="Underline">Nervous System</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></p></td>
<td class="Botrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></p></td>
<td class="Botrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></p></td>
<td class="Botrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span></p></td>
<td class="Botrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </p></td>
<td class="Botrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
<td class="Botrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold"><span class="Underline">Respiratory System</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></p></td>
<td class="Botrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></p></td>
<td class="Botrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold"><span class="Underline">Skin and Appendages</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></p></td>
<td class="Botrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
</tbody>
</table>
<p>Treatment-emergent adverse reactions for certain events were reported at a higher frequency by patients ≥65 years of age compared to patients &lt;65 years [see<span class="Italics"><a href="#Section_8.5"> Use in Specific Populations (8.5)</a></span>].</p>
<p>No consistent differences in the incidences of adverse reactions were observed between male and female patients.</p>
<p>There were insufficient data to assess the impact of race on the incidence of adverse reactions.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_c850e4bd-10d8-47ee-8d7b-d1b4d01ba186"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Meperidine</h2>
<p class="First">Serious, sometimes fatal reactions have been reported in patients treated with concomitant meperidine (e.g., Demerol and other tradenames) and MAO inhibitors including selective MAO-B inhibitors [see<span class="Italics"><a href="#Section_4"> Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_c14db45d-6e02-45f8-a0ed-0c3f85d728ea"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Dextromethorphan</h2>
<p class="First">The combination of MAO inhibitors and dextromethorphan has been reported to cause brief episodes of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> or <span class="product-label-link" type="condition" conceptid="4092397" conceptname="Bizarre behavior">bizarre behavior</span>. Therefore, in view of ZELAPAR’s MAO inhibitory activity, dextromethorphan should not be used concomitantly with ZELAPAR [see<span class="Italics"><a href="#Section_4"> Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_2bbd5626-59dc-4fe7-bf3d-41d4da449ac6"></a><a name="section-7.3"></a><p></p>
<h2>7.3 MAO Inhibitors</h2>
<p class="First">ZELAPAR should not be administered along with other selegiline products (e.g., EMSAM or ELDEPRYL<span class="Sup">®</span>) because of the increased risk of non-selective MAO inhibition that may lead to a <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> [see<span class="Italics"><a href="#Section_4"> Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_124b62ee-08ea-4dff-9785-8c9d24df7fc0"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Sympathomimetic Medications</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span>, including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_726c5147-dd29-40b6-a9be-4732da21e958"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Tyramine/Selegiline Interaction</h2>
<p class="First">The enzyme, monoamine oxidase (MAO) (primarily type A), in the gastrointestinal tract and liver provides protection from ingested amines (e.g., tyramine) that, if absorbed, have the capacity to cause <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> (tyramine reaction). If MAO is inhibited in the gastrointestinal tract and liver, ingestion of exogenous amines contained in some foods such as fermented cheese, herring, or over-the-counter <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>/<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> medicines may be absorbed systemically causing release of norepinephrine and a rise in systemic blood pressure with the potential for <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>. Selective MAO-B inhibitors lose their selectivity for MAO-B when taken in doses higher than recommended<span class="Italics">. </span>Non-selective MAO-A inhibitors or MAO-B inhibitors in higher than recommended doses may result in MAO-A inhibition in the gastrointestinal tract and liver.</p>
<p>Results of a tyramine challenge study indicate that ZELAPAR is relatively selective for MAO-B at the recommended dose. In most cases, there is no need for dietary tyramine restriction in patients prescribed ZELAPAR [see<span class="Italics"><a href="#Section_12.2">  Clinical Pharmacology (12.2)</a></span>] at the recommended dose. Because the selectivity for inhibiting MAO-B diminishes as the dose of ZELAPAR is increased above the recommended daily dose, patients should not take more than 2.5 mg of ZELAPAR daily.</p>
<p>Reports of hypertensive reactions have occurred in patients who ingested tyramine-containing consumables (i.e., food or drink) while receiving swallowed selegiline at the recommended dose (a dose believed to be relatively selective for MAO-B). <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">Hypertensive crisis</span> has also been reported with ZELAPAR use that was not above the recommended dosing.</p>
<p><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_b9d3cfd7-1deb-4981-9380-330fd081c1a6"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors</h2>
<p class="First">Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and swallowed selegiline, or selective serotonin reuptake inhibitors and swallowed selegiline [see<span class="Italics"><a href="#Section_5.2"> Warnings and Precautions (5.2)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_be06ed13-eea0-4821-901a-9a0b141bf83a"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Drugs that Induce CYP450</h2>
<p class="First">Adequate studies have not been done investigating the effect of CYP3A4-inducers on selegiline. Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_045473b3-ac3e-4c22-864f-808db567e565"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Dopaminergic Antagonists</h2>
<p class="First">It is possible that dopamine antagonists, such as antipsychotics or metoclopramide, could diminish the effectiveness of ZELAPAR.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1.1"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Pregnancy Category C</span></h3>
<p class="First">There are no adequate and well-controlled studies in pregnant women. In animal studies, administration of selegiline during pregnancy was associated with developmental toxicity (decreased embryofetal and postnatal offspring growth and survival) at doses greater than those used clinically. ZELAPAR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>In rats administered selegiline orally (5, 10, and 40 mg/kg/day) throughout the period of organogenesis, a decrease in fetal body weight was observed at the mid and high doses. The no-effect dose for embryofetal developmental toxicity in rats (5 mg/kg/day) is approximately 20 times the maximum recommended human dose (MRHD) of 2.5 mg/day on a mg/m<span class="Sup">2</span> basis. </p>
<p>In rabbits administered selegiline orally (5, 30, and 60 mg/kg/day) throughout the period of organogenesis, embryolethality was observed at the highest dose tested and reduced fetal body weight was observed at the mid and high doses. The no-effect dose for embryofetal developmental toxicity in rabbits (5 mg/kg/day) is approximately 40 times the MRHD on a mg/m<span class="Sup">2</span> basis.</p>
<p>In rats administered selegiline orally (0.3, 1, and 10 mg/kg/day) during gestation and lactation, decreases in offspring survival and body weights were observed at the highest dose tested. The no-effect dose for pre- and postnatal developmental toxicity (1 mg/kg/day) is approximately 4 times the MRHD on a mg/m<span class="Sup">2</span> basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Selegiline and metabolites were detected in rat milk at levels higher than those in maternal plasma. It is not known whether this drug or its metabolites are excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when ZELAPAR is administered to a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">The overall incidence of adverse reactions was increased in geriatric patients (<span class="Underline">&gt;</span>65 years) compared to non-geriatric patients (&lt;65 years). Clinical studies did not include a sufficient number of geriatric subjects older than 75 years to determine whether they respond differently to ZELAPAR.</p>
<p>Analysis of adverse reaction incidence in each group was conducted to calculate and compare relative risk (ZELAPAR % / Placebo %) for each treatment. The relative risk was ≥2 fold higher for ZELAPAR treatment in the geriatric patients compared to the non-geriatric patients for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, orthostatic/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> [see <span class="Italics"><a href="#Section_5.4">Warnings and Precautions (5.4)</a></span>]. The incidence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> by measurement of blood pressure was also higher in geriatric patients than in non-geriatric patients. In the geriatric patients, the treatment difference for incidence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> determined by supine and standing blood measurements was 3%.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_c2b674a6-32f4-4221-a2fa-add0241ad02d"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 5 to 9) may require a dose reduction of ZELAPAR (from 2.5 to 1.25 mg daily) depending on the clinical response. ZELAPAR is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score &gt;9) [see<span class="Italics"><a href="#Section_2.2"> Dosage and Administration (2.2)</a></span> and<span class="Italics"><a href="#Section_12.3"> Clinical Pharmacology (12.3)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_86ea3571-fbd0-48c3-b390-fd5443a9e3aa"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment of ZELAPAR is required in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance [CLcr] 30 to 89 mL/min). ZELAPAR is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> [ESRD] (CLcr &lt;30 mL/min) [see<span class="Italics"><a href="#Section_2.3"> Dosage and Administration (2.3)</a></span> and <span class="Italics"><a href="#Section_12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_ef8348ba-b48b-4cda-91ed-c9ac20d70082"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Selegiline</h2>
<p class="First">No specific information is available about clinically significant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with swallowed selegiline or ZELAPAR. However, experience gained during development of the 5 mg swallowed dosage form reveals that some individuals exposed to doses of 600 mg of d,l-selegiline suffered severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor agitation</span>.</p>
<p>Since the selective inhibition of MAO-B by ZELAPAR is achieved only at doses in the range recommended for the treatment of Parkinson’s disease (e.g., 2.5 mg/day), <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> are likely to cause significant inhibition of both MAO-A and MAO-B. Consequently, the signs and symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may resemble those observed with marketed non-selective MAO inhibitors [e.g., tranylcypromine (PARNATE<span class="Sup">®</span>), isocarboxazid (MARPLAN<span class="Sup">®</span>), and phenelzine (NARDIL<span class="Sup">®</span>)]. For this reason, in cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with selegiline, dietary tyramine restriction should be observed for several weeks to avoid the risk of a hypertensive reaction.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_99e0cf28-4988-45d9-b04e-7b9e6b77f7f8"></a><a name="section-9.2"></a><p></p>
<h2>10.2 <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> with Non-Selective MAO Inhibitors</h2>
<p class="First">NOTE: The following description of presenting symptoms and clinical course is based upon <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> descriptions of nonselective MAO inhibitors and does not include information from patients who have overdosed on oral selegiline or ZELAPAR.</p>
<p>Characteristically, signs and symptoms of non-selective MAO inhibitor <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may not appear immediately. Delays of up to 12 hours between ingestion of drug and the appearance of signs may occur. Importantly, the peak intensity of the syndrome may not be reached for upwards of a day following the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has been reported following overdosage. Therefore, immediate hospitalization, with continuous patient observation and monitoring for a period of at least two days following the ingestion of such drugs in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, is strongly recommended.</p>
<p>The clinical picture of MAO inhibitor <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> varies considerably; its severity may be a function of the amount of drug consumed. The central nervous and cardiovascular systems are prominently involved.</p>
<p>Signs and symptoms of overdosage may include, alone or in combination, any of the following: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, faintness, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span>, <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; rapid and <span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span>; <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">precordial pain</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and failure, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cool, <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_58740028-7adb-4386-8cb4-d91adbd67d2e"></a><a name="section-9.3"></a><p></p>
<h2>10.3 Treatment of Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with non-selective MAO inhibitors is symptomatic and supportive. Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage with instillation of charcoal slurry may be helpful in early <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, provided the airway has been protected against <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>. Signs and symptoms of central nervous system stimulation, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, should be treated with diazepam, given slowly intravenously. Phenothiazine derivatives and central nervous system stimulants should be avoided. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span> should be treated with intravenous fluids and, if necessary, blood pressure titration with an intravenous infusion of a dilute pressor agent. It should be noted that adrenergic agents may produce a markedly increased pressor response.</p>
<p>Support respiration, including management of the airway, use of supplemental oxygen, and mechanical ventilatory assistance, as required.</p>
<p>Body temperature should be monitored closely. Intensive management of <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span> may be required. Maintenance of fluid and electrolyte balance is essential.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">ZELAPAR Orally Disintegrating Tablets contain selegiline hydrochloride, a levorotatory acetylenic derivative of phenthylamine. Selegiline hydrochloride is described chemically as: (-)-(R)-N, α-dimethyl-N-2-propynylphenethylamine hydrochloride and its structural formula is:</p>
<div class="Figure">
<a name="id-728225633"></a><img alt="Zelapar Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=380d7717-2a79-42f3-a712-efe5e7696ba0&amp;name=Zelapar%20Chemical%20Structure.jpg">
</div>
<p>Its empirical formula is C<span class="Sub">13</span>H<span class="Sub">17</span>N<span class="Bold">∙</span>HCl, representing a molecular weight of 223.75. Selegiline hydrochloride is a white to almost white crystalline powder that is freely soluble in water, chloroform, and methanol.</p>
<p>ZELAPAR Orally Disintegrating Tablets are available for oral administration (<span class="Bold">not</span> to be swallowed) in a strength of 1.25 mg. Each lyophilized orally disintegrating tablet contains the following inactive ingredients: gelatin, mannitol, glycine, aspartame, citric acid, yellow iron oxide, and grapefruit flavor.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.1.1"></a><a name="section-11.1.1"></a><p></p>
<p class="First">Selegiline is an irreversible inhibitor of monoamine oxidase (MAO), which regulates the metabolic degradation of catecholamines and serotonin in the central nervous system and peripheral tissues. At recommended doses, selegiline is selective for MAO type B (MAO-B), the major form in the brain.  Inhibition of MAO-B activity, by blocking the catabolism of dopamine, may result in increased dopamine levels; however, there is evidence that selegiline may act through other mechanisms to increase dopaminergic activity.</p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Section_12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.2.1"></a><a name="section-11.2.1"></a><p></p>
<p class="First">A pharmacodynamic study investigating daily ZELAPAR doses of 2.5 mg, 5 mg, and 10 mg for tyramine sensitivity showed that increased tyramine sensitivity resulting in <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> (because of MAO-A inhibition and decreased selectivity for MAO-B) occurred with dosing above the recommended level (2.5 mg daily). An increase in tyramine sensitivity for blood pressure responses appears to begin at a dose of 5 mg ZELAPAR daily [see<span class="Italics"><a href="#Section_5.1"> Warnings and Precautions (5.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.1"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>ZELAPAR disintegrates within seconds after placement on the tongue and is rapidly absorbed. Detectable levels of selegiline from ZELAPAR have been measured at 5 minutes after administration, the earliest time point examined.</p>
<p>Selegiline is more rapidly absorbed from the 1.25 or 2.5 mg dose of ZELAPAR (T<span class="Sub">max</span> range: 10-15 minutes) than from the swallowed 5 mg selegiline tablet (T<span class="Sub">max</span> range: 40-90 minutes). Mean (SD) maximum plasma concentrations of 3.34 (1.68) and 4.47 (2.56) ng/mL are reached after single dose of 1.25 and 2.5 mg ZELAPAR compared to 1.12 ng/mL (1.48) for the swallowed 5 mg selegiline tablets (given as 5 mg bid). On a dose-normalized basis, the relative bioavailability of selegiline from ZELAPAR is greater than from the swallowed formulation.</p>
<p>The pre-gastric absorption from ZELAPAR and the avoidance of first-pass metabolism results in higher concentrations of selegiline and lower concentrations of the metabolites compared to the 5 mg swallowed selegiline tablet.</p>
<p>Plasma C<span class="Sub">max</span> and AUC of ZELAPAR were dose proportional at doses between 2.5 and 10 mg daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eb2d162c-255c-4199-a358-db1bbedb377f"></a><a name="section-11.3.2"></a><p></p>
<h3><span class="Bold">Food effects</span></h3>
<p class="First">When ZELAPAR is taken with food, the C<span class="Sub">max</span> and AUC of selegiline are about 60% of those seen when ZELAPAR is taken in the fasted state. Since ZELAPAR is placed on the tongue and absorbed through the oral mucosa, the intake of food and liquid should be avoided 5 minutes before and after ZELAPAR administration [see<span class="Italics"><a href="#Section_2.1"> Dosage and Administration (2.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.4"></a><a name="section-11.3.3"></a><p></p>
<h3><span class="Bold">Distribution</span></h3>
<p class="First">Up to 85% of plasma selegiline is reversibly bound to proteins.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_aa35728b-d04a-4be3-9531-ca0c8783ed29"></a><a name="section-11.3.4"></a><p></p>
<h3><span class="Bold">Metabolism</span></h3>
<p class="First">Following a single dose, the median elimination half-life of selegiline was 1.3 hours at the 1.25 mg dose. Under steady-state conditions, the median elimination half-life increases to 10 hours. Upon repeat dosing, accumulation in the plasma concentration of selegiline is observed both with ZELAPAR and the swallowed 5 mg tablet. Steady state is achieved after 8 days.</p>
<p>Selegiline is metabolized <span class="Italics">in vivo</span> to <span class="Italics">l</span>-methamphetamine and <span class="Italics">N</span>-desmethylselegiline and subsequently to <span class="Italics">l</span>-amphetamine; which in turn are further metabolized to their hydroxymetabolites. </p>
<p>ZELAPAR also produces a smaller fraction of the administered dose recoverable as the metabolites than the conventional, swallowed formulation of selegiline.</p>
<p><span class="Italics">In vitro</span> metabolism studies indicate that CYP2B6 and CYP3A4 are involved in the metabolism of selegiline. CYP2A6 may play a minor role in the metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.5"></a><a name="section-11.3.5"></a><p></p>
<h3><span class="Bold">Elimination</span></h3>
<p class="First">Following metabolism in the liver, selegiline is excreted primarily in the urine as metabolites (mainly as <span class="Italics">l</span>-methamphetamine) and as a small amount in the feces.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6"></a><a name="section-11.3.6"></a><p></p>
<h3><span class="Bold">Special Populations</span></h3>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_d75364ba-9a89-4ff2-b22d-7de3fdc903a0"></a><a name="section-11.3.6.1"></a><p></p>
<h4><span class="Bold">Age</span></h4>
<p class="First">The effect of age on the pharmacokinetics of selegiline following ZELAPAR administration has not been adequately characterized.  </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_87036e5d-5674-4f4f-a545-030dff3d264b"></a><a name="section-11.3.6.2"></a><p></p>
<h4><span class="Bold">Gender</span></h4>
<p class="First">There are no differences between male and female subjects in overall (AUC<span class="Sub">∞</span>), time to maximum exposure (T<span class="Sub">max</span>), and elimination half-life (t<span class="Sub">½</span>) after administration of ZELAPAR. Female subjects have an approximate 25% decrease in C<span class="Sub">max</span> compared to male subjects.  However, since the overall exposure (AUC<span class="Sub">∞</span>) is not different between the genders, this pharmacokinetic difference is not likely to be clinically relevant.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_18cff3b9-44fc-4246-85ef-0d74fb614e5e"></a><a name="section-11.3.6.3"></a><p></p>
<h4><span class="Bold">Race</span></h4>
<p class="First">No studies have been conducted to evaluate the effects of race on the pharmacokinetics of ZELAPAR.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_a0c4ae7d-c4a9-4d12-9e43-0b7e11ea0125"></a><a name="section-11.3.6.4"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h4>
<p class="First">Following once-daily dosing of ZELAPAR 2.5 mg to selegiline steady-state (10 days) in 6 subjects with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr &gt;50 to 89 mL/min) and in 6 subjects with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr &gt;30 to 50 mL/min), AUC and C<span class="Sub">max</span> of selegiline and desmethylselegiline were not substantially different from healthy subjects; however, methamphetamine and amphetamine exposures were increased by 34-67% in subjects with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Following once-daily dosing of ZELAPAR 1.25 mg to steady-state (10 days) in 6 end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> patients, off dialysis, selegiline exposure was not substantially different from that in healthy subjects, however methamphetamine and amphetamine exposures were increased approximately  4-fold compared to healthy subjects [see<span class="Italics"><a href="#Section_2.3"> Dosage and Administration (2.3)</a></span> and <span class="Italics"><a href="#ID_86ea3571-fbd0-48c3-b390-fd5443a9e3aa"> Use in Specific Populations (8.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_b12f7016-445d-4f5f-b219-6d4943d380d5"></a><a name="section-11.3.6.5"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h4>
<p class="First">Subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 5 to 6), received once-daily dosing of ZELAPAR 2.5 mg to selegiline until they attained steady-state (10 days).  The AUC and C<span class="Sub">max</span> of selegiline were 1.5-fold higher and the AUC and C<span class="Sub">max</span> of the metabolite desmethylselegiline were 1.4-fold and 1.2-fold higher. In subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 7 to 9), the AUC of selegiline and desmethylselegeline increased 1.5-fold and 1.8-fold, respectively, whereas the C<span class="Sub">max</span> of selegiline and demethylselegiline were comparable to healthy subjects. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score &gt;9) had a 4-fold increased AUC of selegiline, 3-fold increased C<span class="Sub">max</span> of selegiline, a 1.25-fold increased AUC of desmethylselegeline and 50% reduced C<span class="Sub">max</span> of desmethylselegeline. Methamphetamine and amphetamine metabolite AUC values were not affected by liver dysfunction [see<span class="Italics"><a href="#Section_2.2"> Dosage and Administration (2.2)</a></span> and <span class="Italics"><a href="#ID_c2b674a6-32f4-4221-a2fa-add0241ad02d"> Use in Specific Populations (8.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_87cea256-cf57-4122-a5d4-0a58facef862"></a><a name="section-11.3.6.6"></a><p></p>
<h4><span class="Bold">Drug Interactions</span></h4>
<p class="First">No studies have been conducted to evaluate drug interactions on the pharmacokinetics of ZELAPAR.  </p>
<p>Effect of CYP3A inhibitor itraconazole: Itraconazole (200 mg QD) did not affect the pharmacokinetics of selegiline (single 10 mg oral, swallowed dose).</p>
<p>Although adequate studies to investigate the effect of CYP3A4-inducers on selegiline have not been performed, drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.11"></a><a name="section-11.3.7"></a><p></p>
<h3><span class="Bold">Drug Interaction Studies</span></h3>
<p class="First">No drug interaction studies have been conducted to evaluate the effects of other drugs on the pharmacokinetics of ZELAPAR or the effect of selegiline on other drugs. <span class="Italics">In vitro</span> studies have demonstrated that selegiline is not an inhibitor of CYP450 enzymes. Selegiline and two of its metabolites, methamphetamine and desmethylselegiline, have little or no potential to induce CYP1A2 and CYP3A4/5 under clinical conditions. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_13.1.1"></a><a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis</span></p>
<p>Assessment of the carcinogenic potential of selegiline administered orally to mice and rats is ongoing.</p>
<p>Carcinogenicity studies of selegiline have not been conducted using the buccal route.</p>
<p><span class="Bold">Mutagenesis</span></p>
<p>Selegiline was negative in the <span class="Italics">in vitro</span> bacterial reverse mutation (Ames) assay in and the <span class="Italics">in vivo</span> micronucleus assay. In the <span class="Italics">in vitro</span> chromosomal aberration assay in mammalian cells, selegiline was negative in the absence of metabolic activation but was clastogenic in the presence of metabolic activation.</p>
<p><span class="Bold">Impairment of Fertility</span></p>
<p>When selegiline was administered orally to male (5, 10, and 40 mg/kg/day) and female (1, 5, and 25 mg/kg/day) rats prior to and during mating and continuing in females to gestation day 7, a decreased number of implantations was observed at the highest doses tested. In males, a reduction in sperm count and density was observed at the highest dose tested. The no-effect doses for reproductive impairment in rats (10 mg/kg/day in males and 5 mg/kg/day in females) are approximately 40 (males) and 20 (females) times the maximum recommended human dose of 2.5 mg/day on a mg/m<span class="Sup">2</span> basis. </p>
<p>No fertility studies have been conducted with selegiline using the buccal route.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First">The effectiveness of ZELAPAR as an adjunct to levodopa/carbidopa in the treatment of Parkinson’s disease was established in a multicenter, randomized, placebo-controlled trial (n=140; 94 received ZELAPAR, 46 received placebo) of three months’ duration. Patients randomized to ZELAPAR received a daily dose of 1.25 mg for the first 6 weeks, and a daily dose of 2.5 mg for the last 6 weeks. All patients were treated with concomitant levodopa products and could additionally have been on concomitant dopamine agonists, anticholinergics, amantadine, or any combination of these during the trial. COMT (catechol-O-methyl-transferase) inhibitors were not allowed.</p>
<p>Patients with idiopathic Parkinson’s disease receiving levodopa were enrolled if they demonstrated an average of at least 3 hours of “OFF? time per day on weekly diaries collected during a 2-week screening period. The patients enrolled had a mean duration of Parkinson’s disease of 7 years, with a range from 0.3 years to 22 years.</p>
<p>At selected times during the 12-week study, patients were asked to record the amount of “OFF,? “ON,? “ON with <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>,? or “sleep? time per day for two separate days during the week prior to each scheduled visit. The primary efficacy outcome was the reduction in average percentage daily “OFF? time during waking hours from baseline to the end of the trial (averaging results at Weeks 10 and 12). Both treatment groups had an average of 7 hours per day of “OFF? time at baseline. Table 2 shows the primary efficacy results. Patients treated with ZELAPAR had a 13% reduction from baseline in daily “OFF? time, compared with a 5% reduction for patients treated with placebo. ZELAPAR-treated patients had an average reduction from baseline of “OFF? time of 2.2 hours per day, compared with a reduction of 0.6 hours in placebo-treated patients. </p>
<a name="_RefID0E6VAG"></a><table width="100%">
<caption><span>Table 2: Mean Percentage Change from Baseline in Daily "Off" Hours at End of Treatment (Average of Weeks 10 and 12) for Intent-to-Treat Population</span></caption>
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Change from Baseline</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">- 5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">ZELAPAR</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">- 13%</p></td>
</tr>
</tbody>
</table>
<p>Figure 1 shows the mean daily percent “OFF? time during treatment over the whole study period for patients treated with ZELAPAR vs. patients treated with placebo.</p>
<div class="Figure">
<a name="id-1680959460"></a><img alt="Figure 1 Zelapar" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=380d7717-2a79-42f3-a712-efe5e7696ba0&amp;name=Figure%201.jpg"><p class="MultiMediaCaption">Figure 1: Mean daily percent "OFF" time during treatment over the whole study period for patients treated with ZELAPAR vs. patients treated with placebo </p>
</div>
<p>Figure 1: Mean daily percent "OFF" time during treatment over the whole study period for patients treated with ZELAPAR vs. patients treated with placebo </p>
<p>Figure 1: Mean daily percent "OFF" time during treatment over the whole study period for patients treated with ZELAPAR vs. patients treated with placebo </p>
<p>Figure 1: Mean daily percent "OFF" time during treatment over the whole study period for patients treated with ZELAPAR vs. patients treated with placebo </p>
<p>Dosage reduction of levodopa was allowed during this study if dopaminergic side effects, including <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, emerged. In those patients who had levodopa dosage reduced, the dose was reduced on average by 24% in ZELAPAR-treated patients and by 21% in placebo-treated patients. </p>
<p>No difference in effectiveness based on age (patients &gt;66 years old vs. &lt;66 years) was detected. The treatment effect size in males was twice that in females, but, given the size of this single trial, this finding is of doubtful significance. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">ZELAPAR Orally Disintegrating Tablets are available containing 1.25 mg selegiline hydrochloride in a Zydis<span class="Sup">®</span> formulation. Each <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow tablet is imprinted with a stylized “V?. Ten tablets are contained in a moisture-resistant pouch and packaged in a carton. Neither the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card nor the pouch is child-resistant.</p>
<p>ZELAPAR (selegiline hydrochloride) is available as: NDC 0187-0453-02, carton of 6 pouches (60 tablets).</p>
<p>Store at controlled room temperature, 25°C (77°F); excursions permitted to 15–30°C (59–86°F). Use within 3 months of opening pouch and immediately upon opening individual <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.  Store <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> tablets in pouch.  Potency cannot be guaranteed after 3 months of opening the pouch.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> and Non-Selective Inhibition of MAO Above the Recommended Dose </span></p>
<p>Advise patients (or their caregivers) not to exceed the daily recommended dose of 2.5 mg. Explain the risk of using higher daily doses of ZELAPAR and provide a brief description of the hypertensive tyramine reaction provided. Rare hypertensive reactions with oral selegiline at recommended doses associated with dietary influences have been reported.</p>
<p>Inform patients (or their caregivers) about the potential for MAOI-induced hypertensive reactions and describe their signs and symptoms. Instruct patients to report, immediately, severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or other atypical or unusual symptoms not previously experienced or very high blood pressure.</p>
<p>The possibility exists that very tyramine-rich foods (e.g., aged cheese such as Stilton) could possibly cause an increase in blood pressure. Patients should be advised to avoid certain foods (e.g., aged cheese) containing a very large amount of tyramine while taking recommended doses of ZELAPAR because of the potential for large increases in blood pressure. If patients eat foods very rich in tyramine and do not feel well soon after eating, they should contact their healthcare provider [see<span class="Italics"><a href="#Section_5.1"> Warnings and Precautions (5.1)</a></span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></span></p>
<p>Inform patients if they are taking, or planning to take, any prescription or over-the-counter drugs, especially antidepressants and over-the-counter <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> medications, because there is a potential for interaction with ZELAPAR. Because patients should not use meperidine or certain other analgesics with ZELAPAR, they should contact their healthcare provider before taking analgesics [see<span class="Italics"><a href="#Section_5.2"> Warnings and Precautions (5.2)</a></span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep During Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></span></p>
<p>Advise patients about the potential for sedating effects associated with ZELAPAR, including <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and particularly to the possibility of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while engaged in activities of daily living. Because <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> can be a frequent adverse reaction with potentially serious consequences, patients should neither drive a car nor engage in other potentially dangerous activities until they have gained sufficient experience with ZELAPAR to gauge whether or not it affects their mental and/or motor performance adversely. Advise patients that if they experience increased <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> or new episodes of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep during activities of daily living (e.g., watching television, passenger in a car, etc.) at any time during treatment, they should not drive or participate in potentially dangerous activities until they have contacted their physician. Advise patients not to drive, operate machinery, or work at heights during treatment if they have previously experienced <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and/or have fallen asleep without warning prior to use of ZELAPAR [see<span class="Italics"><a href="#Section_5.3"> Warnings and Precautions (5.3)</a></span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></span></p>
<p>Advise patients that they may develop symptomatic (or asymptomatic) <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> while taking ZELAPAR, especially if they are elderly. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may occur more frequently during initial therapy. Accordingly, caution patients against rising rapidly after sitting or lying down, especially if they have been doing so for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> and especially at the initiation of treatment with ZELAPAR [see<span class="Italics"><a href="#Section_5.4"> Warnings and Precautions (5.4)</a></span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></span></p>
<p>Inform patients that ZELAPAR may cause and/or exacerbate pre-existing <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span> [see<span class="Italics"><a href="#Section_5.5"> Warnings and Precautions (5.5)</a></span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>/<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-Like Behavior </span></p>
<p>Inform patients that <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and other <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior can occur while taking Neupro and that the elderly are at a higher risk than younger patients with Parkinson's disease. Tell patients to report <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior to their health care provider promptly should they develop [see<span class="Italics"><a href="#Section_5.6"> Warnings and Precautions (5.6)</a></span>].</p>
<p><span class="Bold">Impulse Control/Compulsive Behaviors</span></p>
<p>Advise patients that they may experience impulse control and/or compulsive behaviors while taking one or more of the medications generally used for the treatment of Parkinson’s disease, including ZELAPAR. Although it is not proven that the medications caused these events, these urges were reported to have stopped in some cases when the dose was reduced or the medication was stopped. Prescribers should ask patients about the development of new or increased <span class="product-label-link" type="condition" conceptid="4023166" conceptname="Gambling">gambling</span> urges, sexual urges or other urges while being treated with ZELAPAR. Patients should inform their physician if they experience new or increased <span class="product-label-link" type="condition" conceptid="4023166" conceptname="Gambling">gambling</span> urges, increased sexual urges or other intense urges while taking ZELAPAR. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking ZELAPAR [see<span class="Italics"><a href="#Section_5.7"> Warnings and Precautions (5.7)</a></span>].</p>
<p><span class="Bold">Withdrawal Emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></span></p>
<p>Advise patients to contact their healthcare provider if they wish to discontinue ZELAPAR or decrease the dose of ZELAPAR [see<span class="Italics"><a href="#Section_5.8"> Warnings and Precautions (5.8)</a></span>].</p>
<p><span class="Bold">Melanoma</span></p>
<p>Advise patients with Parkinson’s disease that they have a higher risk of developing melanoma. Advise patients to have periodic examinations of their skin by a qualified healthcare professional on a regular basis when using ZELAPAR [see<span class="Italics"><a href="#Section_5.9"> Warnings and Precautions (5.9)</a></span>].</p>
<p><span class="Bold">Irritation of the Buccal Mucosa</span></p>
<p>Inform patients that ZELAPAR may cause irritation of the buccal mucosa including swallowing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4012068" conceptname="Sore mouth">mouth pain</span>, discrete areas of focal reddening, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and/or ulceration [see<span class="Italics"><a href="#ID_fff0680a-257d-443c-810f-e5c15b165a66"> Warnings and Precautions (5.10)</a></span>].</p>
<p><span class="Bold">Risk for Phenylketonuric Patients</span></p>
<p>Advise patients that ZELAPAR contains aspartame which could cause problems in patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span> [see<span class="Italics"><a href="#ID_cd4abdcd-02a5-40aa-9cab-0bf32857be28"> Warnings and Precautions (5.11)</a></span>].</p>
<p><span class="Bold">Instructions for Use</span></p>
<p>Patients should be instructed not to remove the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> from the outer pouch until just prior to dosing. The <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack should then be peeled open with dry hands and the orally disintegrating tablet placed on the tongue, where the tablet will disintegrate. Patients should also avoid drinking liquids or eating food 5 minutes before and after taking ZELAPAR. Use ZELAPAR within 3 months of opening pouch and immediately upon opening individual <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>. Store <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> tablets in pouch. Potency cannot be guaranteed after 3 months of opening the pouch.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="sSign"></a><a name="section-16"></a><p></p>
<p class="First"><br><br>Distributed by:<br>Valeant Pharmaceuticals North America LLC<br>Bridgewater, NJ 08807 USA<br></p>
<p>Manufactured by:<br>Catalent Health, Inc.<br>Swindon, Wiltshire, SN5 8RU, UK</p>
<p>ZELAPAR is a registered trademark of Valeant Pharmaceuticals North America LLC or its related companies. Zydis<span class="Sup">®</span> is a registered trademark of Catalent Pharma Solutions or one of its subsidiaries, used under license. All other trademarks are the trademarks or the registered trademarks of their respective owners.</p>
<p>9387400<br>Rev. 07/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_5bff93da-9c33-4ceb-bd93-cbbf095c24a1"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL </h1>
<p class="First"><span class="Bold">NDC 0187-0453-02</span></p>
<p><span class="Bold"><span class="Italics">Rx Only</span></span></p>
<p><span class="Bold">Zelapar<span class="Sup">®</span> 1.25 mg</span></p>
<p>(selegiline HCl)</p>
<p>Orally Disintegrating Tablets<br></p>
<p><span class="Italics">6 pouches,</span></p>
<p><span class="Italics">each containing</span><br><span class="Italics">10 tablets</span></p>
<p>VALEANT<span class="Sup">®</span></p>
<div class="Figure">
<a name="id-1880998259"></a><img alt="Carton Label - Zelapar " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=380d7717-2a79-42f3-a712-efe5e7696ba0&amp;name=image-01.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZELAPAR 		
					</strong><br><span class="contentTableReg">selegiline hydrochloride tablet, orally disintegrating</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0187-0453</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SELEGILINE HYDROCHLORIDE</strong> (SELEGILINE) </td>
<td class="formItem">SELEGILINE HYDROCHLORIDE</td>
<td class="formItem">1.25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">GRAPEFRUIT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">V</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0187-0453-02</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0187-0453-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021479</td>
<td class="formItem">06/14/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Valeant Pharmaceuticals North America LLC
							(042230623)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions</td>
<td class="formItem"></td>
<td class="formItem">237676320</td>
<td class="formItem">MANUFACTURE(0187-0453)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>be0d2a9e-3f39-49cf-b71d-3a206ad3c3fb</div>
<div>Set id: 380d7717-2a79-42f3-a712-efe5e7696ba0</div>
<div>Version: 3</div>
<div>Effective Time: 20140731</div>
</div>
</div> <div class="DistributorName">Valeant Pharmaceuticals North America LLC</div></p>
</body></html>
